Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin T Ernst

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|March 8, 2008
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric siteAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|March 8, 2008
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitorsAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Bioorganic & Medicinal Chemistry Letters|July 29, 2010
Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric siteAntonio Garrido Montalban, Erik Boman, Chau-Dung Chang, et al.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.
Pageof 2